DrugPatentWatch Database Preview
Drugs in Development Information for Tetrahydrouridine
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for Tetrahydrouridine?
Tetrahydrouridine is an investigational drug.
There have been 17 clinical trials for Tetrahydrouridine.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2009.
The most common disease conditions in clinical trials are Lung Neoplasms, Head and Neck Neoplasms, and Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), EpiDestiny, Inc., and Yogen Saunthararajah.
Summary for Tetrahydrouridine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 93 |
| WIPO Patent Applications | 77 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2009-08-01) |
| Vendors | 24 |
Recent Clinical Trials for Tetrahydrouridine
| Title | Sponsor | Phase |
|---|---|---|
| Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects | EpiDestiny, Inc. | Phase 1 |
| A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease | National Institutes of Health (NIH) | Phase 1 |
| A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease | EpiDestiny, Inc. | Phase 1 |
Clinical Trial Summary for Tetrahydrouridine
Top disease conditions for Tetrahydrouridine
Top clinical trial sponsors for Tetrahydrouridine
US Patents for Tetrahydrouridine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
